NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 48 percent year over year, thanks to continued momentum from its kidney transplant test AlloSure.

For the three months ended June 30, the diagnostics company said revenues rose to $17.8 million from $12.0 million in Q2 2017, beating analysts' average estimate of $15.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.